pharma · Melanoma · Tumor · NKTR
Nektar Therapeutics UK
Nektar Therapeutics UK Limited
NovaPharmaNews editorial coverage mentioning Nektar Therapeutics UK — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 455 Mission Bay Boulevard South, San Francisco, California 94158, US
- Founded
- 1990
- Employees
- 610
- Programs
- 57
- Drugs
- 31
- Patents
- 423
News & analysis
NovaPharmaNews articles mentioning Nektar Therapeutics UK — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Nektar Therapeutics UK — regulatory, clinical, and market analysis.
Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context
Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context, with trial facts, status, and a clear split between active development and regulatory context. This plan is built for analysts, BD teams, and investors comparing clinical-stage autoimmune assets.
Nektar Therapeutics pipeline update: REZPEG, amphotericin B and UK site changes
Nektar Therapeutics’ pipeline remains centered on REZPEG, with active Phase 2 programs in atopic dermatitis and alopecia areata and a completed SLE study. The company also has an amphotericin B-linked program context and recent business changes that matter for BD teams and investors.